Document is current

Article History

Received: 20 November 2017

Revised: 10 April 2018

Accepted: 19 April 2018

First Online: 11 May 2018

Ethics approval and consent to participate

: The hiPSC line 73–56,010-02 was generated from a healthy donor [] participating in the study “Family-Based Genome-Wide Methylation Scan in Neurocognition and Schizophrenia,” in which human subjects were enrolled at the University of Pittsburgh (PITT). The PITT Institutional Review Board approved the study, and subjects enrolled signed written informed consent prior to participation in any study procedures. The hiPSC line was established at the National Institute of Mental Health (NIMH) Center for Collaborative Studies of Mental Disorders (RUCDR). The sample was labeled with a coded ID and without any identifying information. The research subject who provided this sample signed an informed consent that included permission for secondary analyses of samples.The hiPSC line PPMI-51625 was obtained from the Parkinson’s Progression Markers Initiative (PPMI) (). Our experiments involving PPMI-derived reagents were reviewed by the University of Pittsburgh Institutional Review Board, confirming no involvement of human subjects according to the federal regulations [§45 CFR 46.102(f)]. Investigators within the PPMI contributed to collection and reprogramming of patient cells, but did not participate in experimentation, analysis, or writing of this report.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.